March 31, 2021
Authored and Edited by Clinton P. Greub; Brooke M. Wilner; Amanda K. Murphy, Ph.D.
In Mylan Laboratories LTD. v. Janssen Pharmaceutica, N.V., No. 2021-1071 (Mar. 12, 2021), the Federal Circuit granted Janssen’s motion to dismiss Mylan’s appeal. Mylan appealed the Board’s decision not to institute inter partes review of Janssen’s U.S. Patent No. 9,439,906, and sought mandamus relief under the All Writs Act. The Court determined it lacked jurisdiction over Mylan’s direct appeal under 35 U.S.C. § 314(d). Although the Court held it had proper jurisdiction over the request for mandamus, the Court held that Mylan failed to show a clear right to relief. In dicta, the Court expressed its belief that it would be “difficult to imagine a mandamus petition that challenges a denial of institution and identifies a clear and indisputable right to relief.”
For a more detailed analysis of this case, please see Finnegan’s Federal Circuit IP blog.
Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Conference
4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA
October 8-24, 2024
Virtual
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in June 2024
August 22, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.